Medical news in brief: RCN cuts ties with Israeli drug company, MenB vaccine uptake concern, 1 in 8 cancer cases linked to infections, and other stories

AI Summary

UK health officials are concerned that only 26.6% of eligible year 13 leavers in England received their first MenB vaccine dose, amid recent meningitis outbreaks. The roundup also reports US approval of AbbVie's Parkinson’s drug Juvmo and other medical news.

MenB vaccineConcern as most young people miss first doseUK Health Security Agency data showed that just 26.6% of eligible year 13 school leavers in England had had their first dose of the new meningitis B vaccine. The agency expressed “concern” over the figures and noted the risk facing many young people heading to university for the first time. Three serious meningitis outbreaks occurred in England this summer, leaving three patients dead and several others in intensive care.Parkinson’s diseaseUS approves new drugJuvmo (tavapadon), a dopamine agonist, is a new treatment for Parkinson’s disease. Clinical trial results suggest that it is less likely than earlier versions of such medicines to trigger serious side effects, including impulsive behaviour, hallucinations, and blood pressure changes. News of the US approval of the drug was welcomed by the charity Parkinson’s UK, but AbbVie, which makes Juvmo, declined to confirm to The BMJ whether it had applied...